

## Supplementary Figure Legends

**Figure S1:** Effects of NVP-BEZ235 and LY294002 on PI3K $\alpha$  activity using an ADP release (A) or a Maxisorp (B) assay. For both assays (see methods), the activity of the p85/p110 $\alpha$  complex is reported as a percentage of inhibition, for which the 0% represents the activity in absence of inhibitors.

**Figure S2:** Dose-dependent effects on activated Akt levels. PC3M cells were incubated with increasing amounts of NVP-BEZ235 for 30 minutes. Cells were then lysed and cell extracts analyzed by Western-blotting to assess total-, S473P- or T308P-Akt levels.

**Figure S3:** NVP-BEZ235 causes rapid relocalization of FKHRL1 into the nucleus A. Kinetic of FKHRL1-GFP relocalization by NVP-BEZ235. U2OS-GFP-FOXO3A cells were imaged as in B, every minute for a period of 20 minutes after administration of the compound. B. Effects on FKHRL1 induced transcription. U2OS-GFP-FKHRL1 cells were transfected with the pGL3-FKHR-LUC gene reporter, exposed to increasing concentrations of either NVP-BEZ235 (left panel) or LY294002 (right panel). Transcription activation was determined as described in the methods section.

**Figure S4:** NVP-BEZ235 inhibits mTor. Purified mTor from rat brain was used in a kinase reaction using a GST-p70S6K fusion protein as a substrate. Phosphorylated levels are represented as Absorbance Units. B. mTORC2 and mTORC1 phosphorylate 4EBP1 on Serine 46/37 in a time dependent manner. IgG-sepharose-pulldowns of HeLa cells stably expressing either TAP-tagged Rictor (500  $\mu$ g) or TAP-tagged Raptor (30  $\mu$ g) were subjected to in vitro kinase assays with 4EBP1 (Phas) as a substrate for indicated amounts of time at 30° C. Kinase

Maira et al – Figures  
NVP-BEZ235 displays potent antitumor activity  
reaction were analyzed by western-blotting to assess phosphorylation of 4EBP1 on Serine  
46/37.

## **Materials and Methods for Supplementary Figures**

### *ADP-release and MaxiSorp PI3K assays*

For the two PI3K $\alpha$  kinase assays shown in figures S1, the full-length p110/p85 protein from Upstate (#14-602) was used. The ADP-release assay was adapted from a previously described method (30). PI3K $\alpha$  was incubated for 60 min at room temperature in 96-well half-area black microplates (Corning #3694) in 50  $\mu$ l medium containing 10  $\mu$ M PIP(4,5)diC<sub>8</sub> (Avanti Polar Lipids #850185P), 20  $\mu$ M ATP (Sigma #A7699), 5 mM MgCl<sub>2</sub>, 30 mM KCl, 70 mM NaCl, 0.4 mM phosphoenolpyruvate, 10 unit/ml pyruvate kinase (Sigma #P9136), 20 mM Tris-HCl pH7.4, 0.1 mg/ml  $\gamma$ -globulin (Sigma #G5009), 0.1 mM EGTA, and 1% DMSO. The reaction was started by adding PI3K $\alpha$  (0.5  $\mu$ g/ml, <2.5 nM) and stopped by adding 50  $\mu$ l of 160 mM phosphate buffer pH6.0 containing 0.02% Triton X-100, 20 U/ml horseradish peroxidase (Sigma #P2088), 2 U/ml pyruvate oxidase (Sigma #P4591), 0.4 mM TPP, 20  $\mu$ M FAD, and 20  $\mu$ M Amplex<sup>®</sup> Red (Molecular Probes #A12222). Fluorescence was read after 5 min in a GeniosPro<sup>™</sup> reader (Tecan, Switzerland) with 540 nm excitation and 590 nm emission filters. For the The MaxiSorp<sup>™</sup> assay (31), 50  $\mu$ l/well of a 1:1 mixture of 100  $\mu$ g/ml L- $\alpha$ -phosphatidylinositol (Avanti Polar Lipids #840044C) and L- $\alpha$ -phosphatidylserine (Avanti Polar Lipids #840032C) dissolved in chloroform:ethanol (2.2:7.8) was pipetted into 96-well MaxiSorp<sup>™</sup> plates (Nunc #436110). The solvents were evaporated at room temperature and plates were washed with Tris-buffered saline (TBS, pH7.4). PI3K $\alpha$  was incubated for 60 min at room temperature in coated plates in 50  $\mu$ l medium containing [ $\gamma$ <sup>33</sup>P]-ATP (~6 kBq/well; Amersham #AH9968), 0.5  $\mu$ M ATP (or higher as indicated in Fig. 1-2), 5 mM MgCl<sub>2</sub>, 150

Maira et al – Figures

NVP-BEZ235 displays potent antitumor activity

mM NaCl, 25 mM Tris-HCl pH7.4, and 1% DMSO. The reaction was started by adding PI3K $\alpha$  (0.4  $\mu$ g/ml, <2 nM) and stopped by adding 50  $\mu$ l of 50 mM EDTA. Plates were washed twice with TBS and dried; 100  $\mu$ l/well MicroScint<sup>TM</sup> PS (Packard) was added, and bound radioactivity was determined using a TopCount<sup>TM</sup> (Packard) counter. The Michaelis-Menten kinetics of ATP was similar in the ADP release and Maxisorp assays ( $K_m$  =26  $\mu$ M;  $V_{max}$  =110 nmol.mg<sup>-1</sup>.min<sup>-1</sup>). The inhibitory effect of NVP-BEZ235 and LY294002 was evaluated by nonlinear curve fitting with the 4-parameter logistic equation  $y=A+(B-A)/(1+((10^C)/x)^D)$  where A is the minimum (%), B the maximum (%), C the log IC<sub>50</sub> and D the Hill coefficient (Model 203 of XLfit<sup>TM</sup>). Independent experiments (n=2-5) were fitted simultaneously with shared parameters using the Global fit wizard of XLfit.

#### ***K-Lisa mTor assay***

The K-LISA<sup>TM</sup> mTOR activity kit was from Calbiochem (ref #CBA055). Briefly, Inhibitors were incubated with mTOR enzyme for 30 minutes on ice. This mixture was then transferred to a glutathione-coated 96-well plate pre-incubated with GST-p70<sup>S6K</sup> recombinant protein. Kinase reactions were initiated by adding kinase buffer containing 100  $\mu$ M ATP and were incubated for 30 minutes at 30°C. mTor activity was quantified using an anti-phospho Thr389-HRP conjugate detection system.

#### ***mTORC1 and mTORC2 assay***

Sub-confluent HeLa cells stably expressing either N-terminally TAP-tagged versions of Rictor or Raptor were lysed (lysis buffer: 40mM Hepes (pH7.5), 120mM NaCl, 1mM EDTA, 0.2% CHAPS, 50mM beta-glycerophosphate, 50mM NaF, 1mM Na<sub>3</sub>VO<sub>4</sub>, 40mg/ml PMSF, 1mM DTT, EDTA-free protease inhibitors (Roche)) and protein concentrations were determined. 500 $\mu$ g (TAP-Rictor) or 30 $\mu$ g (TAP-Raptor) of total cell lysate / sample were

Maira et al – Figures

NVP-BEZ235 displays potent antitumor activity

subjected to a pulldown with 15  $\mu$ l IgG-sepharose beads (1:1 slurry, Amersham) for 2h at 4°C.

IgG-sepharose pull-downs were washed 3 times with washing buffer (40 mM Hepes (pH7),

120mM NaCl, 0.3% CHAPS, 10 mM beta-glycerophosphate, 10mM NaF, 10 mM NaN<sub>3</sub>, 10

mM NaPPi, 20  $\mu$ g/ml heparin, 0.5 mM benzamidine / HCl, 1.5 mM Na<sub>3</sub>VO<sub>4</sub>, 1 mg/ml PMSF,

1 mM DTT, EDTA-free protease inhibitors and prior to the kinase assay samples were

pretreated with indicated amounts of NVP-BEZ235 at a final concentration of 0.005% DMSO

for 15min at 4°C. Then, samples were subjected to kinase assays in a volume of 50 $\mu$ l

reaction buffer (40mM Hepes (pH7), 120mM NaCl, 0.3% CHAPS, 2 $\mu$ g/ml heparin, 1mM

DTT, 10mM MnCl<sub>2</sub>, 100  $\mu$ M ATP, 1 $\mu$ g/ $\mu$ l 4E-BP1/PHAS (Stratagene), 1 $\mu$ M PKI (Protein

kinase A inhibitor – Calbiochem) at 30°C for 30min (TAP-Rictor) or 20min (TAP-Raptor) if

not indicated otherwise. The reaction was stopped with 25 $\mu$ l of 4x SDS-sample buffer.

Samples were boiled for 5min and loaded onto 12% SDS gels. Gels were transferred to

nitrocellulose membranes and phosphorylation of 4EBP1 on Serine 46/37 was detected with

phosphor-specific antibodies from Cell Signaling Technology.

### ***Forkhead Transcription assay***

U2OS-GFP-FKHRL1 cells (density of  $3.75 \times 10^5$  cells/mL) were transiently transfected with

pGL3-FKHR-LUC reporter gene (8  $\mu$ g DNA per T175 cell culture flask) using Lipofectamine

2000 (Invitrogen, Carlsbad, CA) and were seeded into white Greiner 384 well plates. After an

incubation period of 18 hours at 37°C and 5% CO<sub>2</sub>, 10  $\mu$ M compound was added for 12 hours.

SteadyGlo (Promega, Madison, WI) reagent was dispensed into the plates and after an

incubation time of 20 min on a shaker the luminescence was read on the Viewlux (Perkin

Elmer, Waltham,MA).